近日，华医榜·2024中国生物医药科技创新价值榜颁奖典礼于上海盛大召开，标新生物入选华医榜2024中国生物医药科技创新价值榜“最具成长性小分子创新药企业TOP10”榜单！
注：以上图片素材均来源于“华医榜·2024中国生物医药科技创新价值榜”
小分子创新药榜单主要聚焦具有小分子创新药管线，具有显著临床价值且研发进展相对领先的企业。上榜企业普遍重视研发投入，不断推动小分子药物的创新，关注国内市场的同时也在积极拓展国际市场。本次获颁最具成长性小分子创新药企业TOP10，彰显了业内专家对于标新生物在小分子创新研发领域的成长力及综合实力的高度认可。
Recently,
the grand ceremony of the "2024 China Biopharmaceutical Technology
Innovation Value List" by Huayi was held in Shanghai, where Gluetacs Therapeutics
was selected for the Huayi 2024 China Biopharmaceutical Technology Innovation
Value List Top 10 Small Molecule Innovative Drug Companies with the Most
Growing Potential.
The "2024 China Biopharmaceutical Technology Innovation Value List" aims to identify innovative companies in the biopharma field that truly have industry influence and leadership. The list is divided into three series: Corporate Value List, Financial Institutions List, and Park List. The Corporate Value List is further divided into 10 major areas: small molecule innovative drugs, biologics, traditional Chinese medicine, vaccines, cell and gene therapy, innovative medical devices, in vitro diagnostics, consumer healthcare, digital health, and CXO. Based on the quantitative growth evaluation criteria for enterprises that Huayi Research Institute has refined over the years, combined with basic processes such as questionnaire surveys, corporate interviews, data analysis, and verification, the review panel standardizes and quantifies the dynamic data of shortlisted biopharma companies and institutions, thereby selecting the enterprises with significant industry value for the year and forming an objective third-party evaluation list within the industry.
The small molecule innovative drug list primarily focuses on companies with pipelines of small molecule innovative drugs that have significant clinical value and are relatively advanced in research and development. The listed companies generally place a high emphasis on R&D investment, continuously promoting innovation in small molecule drugs. Besides paying attention to the domestic market, they are also actively expanding into international markets. Being awarded the Top 10 Small Molecule Innovative Drug Companies with the Most Growing Potential highlights the industry experts' high recognition of Gluetacs Therapeutics' growth potential and comprehensive strength in the field of small molecule innovative drug R&D.
关于标新生物
标新生物自成立以来受到业内的广泛关注，连续三年获得上海市科技型中小企业称号，连续两年入选华医榜中国生物医药科技创新价值榜最具成长性小分子创新药企业TOP10，荣获2024专精特新中小企业和创新型中小企业称号、2024年度临港新片区科创新锐企业称号、2023上海市高价值专利运营大赛百强、2023中国海归创业大赛三等奖、2023临港杯第九届创青春上海青年创新创业大赛一等奖、2022浦东新区全球高校校友科创大赛二等奖，2022中国创新制药企业TOP10、2022第十一届中国创新创业大赛成长组全国赛优秀企业奖、2022第6届医疗健康投资卓悦榜年度生物医药最佳企业、2022第五届中国创翼创业创新大赛上海选拔赛浦东赛区十佳创翼奖、2022浦东新区全球高校校友科创大赛二等奖、2022Venture50新芽榜150强、2021年度全国颠覆性技术创新大赛优秀项目、2021年第二届生物产业年度攀登榜年度最具投资潜质的新锐BioTech、2021中国生物医药产业链创新风云榜金马奖最具关注度新锐企业TOP10奖项。公司陆续获得多项科技部和上海市科委资金支持，纳入临港新片区前沿产业优秀人才安家补贴、重点产业人才补贴、人才引进重点机构名单，知识产权管理体系获得中国专利保护协会认证，多位团队核心成员陆续获得临港新片区十大科技创新先锋人物、谈家桢生命科学产业化奖、杨雄科技创业奖、东方英才创业青年领军人才、上海高层次海外人才和上海市浦江人才等称号。公司也先后成为上海科技大学创新型硕士和工程博士培养单位，并先后与十多位海内外专家教授进行科研研究合作。
注：转载请注明出处，感谢您对标新生物的关注
